Clinical Trials Logo

Clinical Trial Summary

This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03985007
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact
Status Completed
Phase Phase 2
Start date January 1, 2018
Completion date March 16, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04050280 - CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Phase 2
Terminated NCT03063203 - Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Phase 2
Recruiting NCT04347616 - Natural Killer-cell Therapy for Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT02957032 - A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1